Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacopeia, Inc. (ACCL) (Prev: PCOP) -- Ignore unavailable to you. Want to Upgrade?

To: John Dwyer who wrote (32)	11/7/1997 5:51:00 PM
From: Susan Rodney	Read Replies (2) \| Respond to of 179

John, I'm glad that you are finding our website useful. We too think that ArQule is a very respectable company. Pharmacopeia and ArQule are in slightly different businesses, as you've probably surmised. ArQule is quite adept at robotic synthesis, simply the synthesis of chemical compounds using robots. Robotic synthesis is certainly more efficient than traditional synthesis methods, but less efficient than pool and split synthesis, and is not proprietary or unique. Pharmacopeia's ECLiPS technology, however, is patented and allows for the rapid synthesis of large numbers of compounds. For comparison sake, Pharmacopeia is currently making approximately 1 million compounds per year. By contrast, a typical robotic synthesis company makes between 150,000 and 200,000 compounds per year. And in drug discovery, numbers are the name of the game! Sue